Acceleron Pharma, an SJE Group investment, has appointed Dr Kemal Malik to its Board of Directors. Dr Malik, who is currently a member of the Board of Management of Bayer AG, will officially join the Acceleron Board effective January 1, 2020.
Dr. Malik has served on the Board of Management of Bayer AG since 2014, with responsibility for Innovation across the Bayer group. His career at Bayer began in 1995 as Head of Metabolic Medicine and Oncology for Europe. He later served as Head of Global Medical Development, before being appointed in 2004 as Head of Global Development and Chief Medical Officer as well as a member of the Executive Committee of Bayer HealthCare AG. Dr. Malik received his medical qualification from the University of London.
His global development and innovation experience across a range of therapeutic areas should prove enormously valuable in helping to guide Acceleron through its exciting transition from a clinical-stage organisation to a fully-integrated biopharmaceutical company.
The SJE Group congratulates Dr Malik, Dr Francois Nader (Chairman of Acceleron Pharma) and the rest of the Board for this appointment.